EYE » Topics » 3. Cash, Cash Equivalents and Marketable Securities

This excerpt taken from the EYE 8-K filed May 30, 2007.

3. Cash, Cash Equivalents and Marketable Securities

The Company’s portfolio of cash, cash equivalents and marketable securities are as follows:

 

     March 31,
2007
   December 31,
2006

Cash and money market funds

   $ 43,845,126    $ 12,597,242

Agency bonds – short-term

     42,000,000      69,000,000

Agency bonds – long-term

     12,000,000      22,000,000

At March 31, 2007, all of the Company’s investments are classified as held-to-maturity and are reported at amortized cost that approximates fair value as the Company has the positive intent and ability to hold these securities to maturity. As of March 31, 2007 and December 31, 2006, the long term agency bonds had maturity dates within 24 months and all other investments had maturities within 12 months.

This excerpt taken from the EYE 8-K filed Apr 23, 2007.

2.    Cash, Cash Equivalents and Marketable Securities

The Company’s portfolio of cash, cash equivalents and marketable securities is made up of the following at December 31:

 

      2006    2005

Cash and money market funds

   $ 12,597,242    $ 11,198,665

Agency bonds—short term

     69,000,000      35,000,000

Agency bonds—long term

     22,000,000      44,000,000

At December 31, 2006, all of the Company’s investments are classified as held-to-maturity and are reported at amortized cost that approximates fair value as the Company has the positive intent and ability to hold these securities to maturity. As of December 31, 2006 and 2005, the long term agency bonds had maturity dates within 24 months and all other investments had maturities within 12 months.

EXCERPTS ON THIS PAGE:

8-K
May 30, 2007
8-K
Apr 23, 2007

"3. Cash, Cash Equivalents and Marketable Securities" elsewhere:

Boston Scientific (BSX)
ABIOMED (ABMD)
Conceptus (CPTS)
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki